Literature DB >> 25890799

Efficacy endpoints for idiopathic pulmonary fibrosis trials.

Luca Richeldi1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25890799     DOI： 10.1016/S2213-2600(15)00146-0

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  2 in total

Review 1.  Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.

Authors:  Thomas Morel; Stefan J Cano
Journal:  Orphanet J Rare Dis       Date:  2017-11-02       Impact factor: 4.123

2.  Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.

Authors:  Sara De Biasi; Stefania Cerri; Elena Bianchini; Lara Gibellini; Elisa Persiani; Gloria Montanari; Fabrizio Luppi; Cristiano Matteo Carbonelli; Luigi Zucchi; Marialuisa Bocchino; Alessandro Sanduzzi Zamparelli; Carlo Vancheri; Giacomo Sgalla; Luca Richeldi; Andrea Cossarizza
Journal:  BMC Med       Date:  2015-11-09       Impact factor: 8.775
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.